2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 76

Whole Blood Targeted Bisulfite Pyrosequencing Identifies Differentially Methylated Regions within Major Histocompatibility Complex (MHC) of Patients with Rheumatoid Arthritis
Abstract Number: 2027

Whole Exome Trio Sequencing Implicates DOCK2 in Juvenile Idiopathic Arthritis
Abstract Number: 228

Widespread Chronic Use of Proton-Pump Inhibitors and Potential for Drug-Drug Interactions in Rheumatoid Arthritis and Lupus Patients
Abstract Number: 2468

Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Abstract Number: 835

WITHDRAWN
Abstract Number: 1175

Withdrawn
Abstract Number: 1184

Withdrawn
Abstract Number: 1640

Work Disability in Psoriatic Arthritis Patients
Abstract Number: 1156

Work Productivity and Activity Impairment in Patients with Rotator Cuff Tendinopathy
Abstract Number: 1792

Work Productivity Is Impaired in Patients with Behcet’s Syndrome
Abstract Number: 2177

Workforce Requirements in Rheumatology: A Systematic Literature Reviewinforming the Development of a Workforce Prediction Risk of Bias Tool and the EULAR Points to Consider
Abstract Number: 1439

Yellow Fever Vaccination in Brazil: Short-Term Safety in Pediatric Autoimmune Rheumatic Diseases
Abstract Number: 753

Young SLE Patients Have Higher Coronary Artery Calcium Scores Compared with Population Controls

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].